Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly

David P. Salmon, Steven H. Ferris, Ronald G. Thomas, Mary Sano, Jeffery L. Cummings, Reisa A. Sperling, Ronald Carl Petersen, Paul S. Aisen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Method: Cognitive tests were administered at baseline and at four subsequent annual evaluations to 417 nondemented participants (172 men, 245 women) between the ages of 74 and 93 (M = 79.13 ± 3.34). APOE genotyping was available for 286 of the participants. Results: Four-year decline was evident on measures of orientation, memory, executive function, and language. Faster decline was evident in APOE ε4+ (a genetic risk factor for AD; n = 73) than in ε4- participants (n = 213), even after controlling for education, gender, ethnicity, and baseline functional and cognitive abilities. This discrepancy increased with age, indicating an Age × Genotype interaction. Conclusion: These results are consistent with population-based studies, and extend the findings to a carefully screened sample that meets inclusion and exclusion criteria for an AD primary prevention trial. The interaction between age and APOE genotype on rate of decline suggests that preclinical disease may be overrepresented in older ε4+ individuals. Thus, APOE genotype and age should be considered in the design of AD primary prevention treatment trials.

Original languageEnglish (US)
Pages (from-to)391-401
Number of pages11
JournalNeuropsychology
Volume27
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Apolipoproteins E
Alzheimer Disease
Genotype
Primary Prevention
Apolipoprotein E4
Aptitude
Executive Function
Language
Cognitive Dysfunction
Education
Alzheimer's Disease
Therapeutics
Population

Keywords

  • Aging
  • Apolipoprotein E
  • Cognitive decline

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Arts and Humanities (miscellaneous)

Cite this

Salmon, D. P., Ferris, S. H., Thomas, R. G., Sano, M., Cummings, J. L., Sperling, R. A., ... Aisen, P. S. (2013). Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology, 27(4), 391-401. https://doi.org/10.1037/a0032707

Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. / Salmon, David P.; Ferris, Steven H.; Thomas, Ronald G.; Sano, Mary; Cummings, Jeffery L.; Sperling, Reisa A.; Petersen, Ronald Carl; Aisen, Paul S.

In: Neuropsychology, Vol. 27, No. 4, 07.2013, p. 391-401.

Research output: Contribution to journalArticle

Salmon, DP, Ferris, SH, Thomas, RG, Sano, M, Cummings, JL, Sperling, RA, Petersen, RC & Aisen, PS 2013, 'Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly', Neuropsychology, vol. 27, no. 4, pp. 391-401. https://doi.org/10.1037/a0032707
Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul;27(4):391-401. https://doi.org/10.1037/a0032707
Salmon, David P. ; Ferris, Steven H. ; Thomas, Ronald G. ; Sano, Mary ; Cummings, Jeffery L. ; Sperling, Reisa A. ; Petersen, Ronald Carl ; Aisen, Paul S. / Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. In: Neuropsychology. 2013 ; Vol. 27, No. 4. pp. 391-401.
@article{137350fc05bd4e468557b03f3d3acf88,
title = "Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly",
abstract = "Objective: This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Method: Cognitive tests were administered at baseline and at four subsequent annual evaluations to 417 nondemented participants (172 men, 245 women) between the ages of 74 and 93 (M = 79.13 ± 3.34). APOE genotyping was available for 286 of the participants. Results: Four-year decline was evident on measures of orientation, memory, executive function, and language. Faster decline was evident in APOE ε4+ (a genetic risk factor for AD; n = 73) than in ε4- participants (n = 213), even after controlling for education, gender, ethnicity, and baseline functional and cognitive abilities. This discrepancy increased with age, indicating an Age × Genotype interaction. Conclusion: These results are consistent with population-based studies, and extend the findings to a carefully screened sample that meets inclusion and exclusion criteria for an AD primary prevention trial. The interaction between age and APOE genotype on rate of decline suggests that preclinical disease may be overrepresented in older ε4+ individuals. Thus, APOE genotype and age should be considered in the design of AD primary prevention treatment trials.",
keywords = "Aging, Apolipoprotein E, Cognitive decline",
author = "Salmon, {David P.} and Ferris, {Steven H.} and Thomas, {Ronald G.} and Mary Sano and Cummings, {Jeffery L.} and Sperling, {Reisa A.} and Petersen, {Ronald Carl} and Aisen, {Paul S.}",
year = "2013",
month = "7",
doi = "10.1037/a0032707",
language = "English (US)",
volume = "27",
pages = "391--401",
journal = "Neuropsychology",
issn = "0894-4105",
publisher = "American Psychological Association Inc.",
number = "4",

}

TY - JOUR

T1 - Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly

AU - Salmon, David P.

AU - Ferris, Steven H.

AU - Thomas, Ronald G.

AU - Sano, Mary

AU - Cummings, Jeffery L.

AU - Sperling, Reisa A.

AU - Petersen, Ronald Carl

AU - Aisen, Paul S.

PY - 2013/7

Y1 - 2013/7

N2 - Objective: This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Method: Cognitive tests were administered at baseline and at four subsequent annual evaluations to 417 nondemented participants (172 men, 245 women) between the ages of 74 and 93 (M = 79.13 ± 3.34). APOE genotyping was available for 286 of the participants. Results: Four-year decline was evident on measures of orientation, memory, executive function, and language. Faster decline was evident in APOE ε4+ (a genetic risk factor for AD; n = 73) than in ε4- participants (n = 213), even after controlling for education, gender, ethnicity, and baseline functional and cognitive abilities. This discrepancy increased with age, indicating an Age × Genotype interaction. Conclusion: These results are consistent with population-based studies, and extend the findings to a carefully screened sample that meets inclusion and exclusion criteria for an AD primary prevention trial. The interaction between age and APOE genotype on rate of decline suggests that preclinical disease may be overrepresented in older ε4+ individuals. Thus, APOE genotype and age should be considered in the design of AD primary prevention treatment trials.

AB - Objective: This study examined the impact of age and apolipoprotein E (APOE) genotype on the rate of cognitive decline in nondemented elderly participants in a simulated Alzheimer's disease (AD) primary prevention treatment trial carried out by the Alzheimer's Disease Cooperative Study. Method: Cognitive tests were administered at baseline and at four subsequent annual evaluations to 417 nondemented participants (172 men, 245 women) between the ages of 74 and 93 (M = 79.13 ± 3.34). APOE genotyping was available for 286 of the participants. Results: Four-year decline was evident on measures of orientation, memory, executive function, and language. Faster decline was evident in APOE ε4+ (a genetic risk factor for AD; n = 73) than in ε4- participants (n = 213), even after controlling for education, gender, ethnicity, and baseline functional and cognitive abilities. This discrepancy increased with age, indicating an Age × Genotype interaction. Conclusion: These results are consistent with population-based studies, and extend the findings to a carefully screened sample that meets inclusion and exclusion criteria for an AD primary prevention trial. The interaction between age and APOE genotype on rate of decline suggests that preclinical disease may be overrepresented in older ε4+ individuals. Thus, APOE genotype and age should be considered in the design of AD primary prevention treatment trials.

KW - Aging

KW - Apolipoprotein E

KW - Cognitive decline

UR - http://www.scopus.com/inward/record.url?scp=84887650863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887650863&partnerID=8YFLogxK

U2 - 10.1037/a0032707

DO - 10.1037/a0032707

M3 - Article

C2 - 23876113

AN - SCOPUS:84887650863

VL - 27

SP - 391

EP - 401

JO - Neuropsychology

JF - Neuropsychology

SN - 0894-4105

IS - 4

ER -